1 / 5

Hepatitis C Virus (HCV) Coinfection: Don’t Stand Still Just Because the Landscape Looks Better

Hepatitis C Virus (HCV) Coinfection: Don’t Stand Still Just Because the Landscape Looks Better. Stuart C. Ray, MD, FIDSA Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Program The Johns Hopkins University School of Medicine Baltimore, Maryland.

menefer
Download Presentation

Hepatitis C Virus (HCV) Coinfection: Don’t Stand Still Just Because the Landscape Looks Better

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hepatitis C Virus (HCV) Coinfection: Don’t Stand Still Just Because the Landscape Looks Better Stuart C. Ray, MD, FIDSAProfessor of Medicine and Oncology Director, Infectious Diseases Fellowship ProgramThe Johns Hopkins UniversitySchool of MedicineBaltimore, Maryland From SC Ray, MD, at Chicago, IL: May 20, 2013, IAS-USA.

  2. HCV DAA Glossary

  3. DAA Regimens in Phase 3 Trials *Subgenotype 1b only

  4. Telaprevir Added to P+Rin patients with HIV and HCV-1 Sulkowski MS, et al. NEJM 2013

  5. Resistance: Common Themesand Some Differences • Nonsuppressive therapy generates resistance • Combination therapy: • Reduces risk of resistance with HIV and HCV • Not required for HBV (monotherapy is effective) • For HIV and HBV, resistance is “permanent” • Not known for HCV

More Related